Friday, 16 October 2026European Markets

MAREL Stock Over 20% Down In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of MAREL (AEX-Index: MAREL.AS) fell by a staggering 20.82% in 5 sessions from €3.89 to €3.08 at 05:08 EST on Wednesday, following the last session's downward trend. AEX-Index is falling 0.57% to €748.38, following the last session's downward trend.

About MAREL

Marel hf. develops, distributes, and sells solutions, software, and services to food processing industries in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. The company's Poultry Processing segment offers integrated systems, software, and services for processing broilers, turkeys, and ducks. Its Meat Processing segment supplies primary, secondary, and further processing equipment, systems, software, and services of pork, beef, veal, and sheep. The company's Fish Processing segment offers equipment, systems, software, and services for farmed and wild salmon and whitefish processing. Its Plant, pet and feed segment provides solutions and services to the pet food, plant-based protein, and aqua feed markets. Marel hf. was founded in 1977 and is based in Garðabær, Iceland.

Earnings Per Share

As for profitability, MAREL has a trailing twelve months EPS of €0.07.

PE Ratio

MAREL has a trailing twelve months price to earnings ratio of 44. Meaning, the purchaser of the share is investing €44 for every euro of annual earnings.

Volatility

MAREL's last week, last month's, and last quarter's current intraday variation average was a negative 7.77%, a negative 0.87%, and a positive 2.04%.

MAREL's highest amplitude of average volatility was 7.97% (last week), 2.89% (last month), and 2.04% (last quarter).

More news about MAREL (MAREL.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com